Antiepileptic drugs are pharmaceutical agents used in the treatment and prevention of epileptic seizures. They help manage or halt clinical seizures in patients suffering from epilepsy by reducing neuronal excitability and synaptic transmission. Various antiepileptic drugs available in the market include first generation drugs like carbamazepine, phenytoin and barbiturates or second generation drugs such as lamotrigine, gabapentin, levetiracetam and topiramate. Precision medicine techniques are helping researchers develop targeted antiepileptic drugs with improved efficacy and lowered side effects.
Global Antiepileptic Drugs Market is estimated to be valued at US$ 7.01 billion in 2023, and is expected to reach US$ 8.81 billion by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 3.3% during the forecast period (2023-2030).
Key Takeaways
Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Shanghai Zhimeng Biopharma, Inc., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., IAMA Therapeutics, Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Marinus Pharmaceuticals, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.
The increasing prevalence of epilepsy globally and launch of novel drugs are fueling market growth. Precision medicine approaches are enabling development of personalized antiepileptic therapies.
Technological advancements such as pharmacogenomics and personalized medicine are helping researchers develop targeted Antiepileptic drugs Market Demand with improved efficacy and safety profiles.
Market Drivers
Growth in the antiepileptic drugs market is attributed to rising geriatric population worldwide which are more prone to develop epilepsy. According to the World Health Organization (WHO), around 50 million people across the globe suffer from epilepsy making it one of the most common neurological diseases globally. Therefore, increasing prevalence of epilepsy drives the demand for antiepileptic drugs for effective treatment and management of seizures.
Current challenges in Antiepileptic Drugs Market:
Poor medication adherence among epileptics remains one of the major challenges faced. Nonadherence to antiepileptic drug therapy can lead to poorer seizure control and increased risk of accidents and injuries. Other challenges include high out-of-pocket costs for medications, particularly for the uninsured population, undesirable side effects of antiepileptic drugs such as drowsiness, dizziness, and difficulty with concentration, social stigma about epilepsy and lack of awareness which leads to incorrect diagnosis and treatment delays.
SWOT Analysis
Strength: Advancements in novel drug delivery systems and drug development offer improved efficacy and safety. Growing awareness campaigns help reduce stigma.
Weakness: Limited options for treatment-resistant epilepsy. Side effects still exist due to diverse mechanisms of action.
Opportunity: Untapped emerging markets hold huge potential. Personalized therapies based on disease subtypes/biomarkers could optimize treatments.
Threats: Patent expiries of blockbuster drugs increase competition. Stringent regulations for approval delays market entry.
Geographically, North America dominates the antiepileptic drugs market in terms of value. This is attributed to the rising prevalence of epilepsy in the US and Canada and high healthcare spending in the region. The Asia Pacific region is expected to be the fastest growing market during the forecast period primarily due to the large patient pool, growing healthcare infrastructure and increasing healthcare expenditure.
In terms of value, the US market accounted for the largest share of the global antiepileptic drugs market in 2021 owing to established healthcare infrastructure, high treatment rates, and presence of major market players in the country. China is expected to be the fastest growing antiepileptic drugs market in Asia Pacific region owing to large population suffering from epilepsy and improvements in healthcare facilities and expanded insurance coverage in the region.
Get this Report in Japanese Language:
Get this Report in Korean Language:
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment